- Home
- GS vs AMGN Comparison
GS vs AMGN Comparison
Compare GS & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GS
- AMGN
- Stock Information
- Founded
- GS 1869
- AMGN 1980
- Country
- GS United States
- AMGN United States
- Employees
- GS N/A
- AMGN N/A
- Industry
- GS Investment Bankers/Brokers/Service
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GS Finance
- AMGN Health Care
- Exchange
- GS Nasdaq
- AMGN Nasdaq
- Market Cap
- GS 182.7B
- AMGN 156.2B
- IPO Year
- GS 1999
- AMGN N/A
- Fundamental
- Price
- GS $524.87
- AMGN $312.64
- Analyst Decision
- GS Buy
- AMGN Buy
- Analyst Count
- GS 17
- AMGN 21
- Target Price
- GS $585.88
- AMGN $323.26
- AVG Volume (30 Days)
- GS 3.1M
- AMGN 3.0M
- Earning Date
- GS 04-14-2025
- AMGN 05-01-2025
- Dividend Yield
- GS 2.29%
- AMGN 3.04%
- EPS Growth
- GS 77.31
- AMGN N/A
- EPS
- GS 40.54
- AMGN 7.56
- Revenue
- GS $52,164,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- GS $12.74
- AMGN $7.36
- Revenue Next Year
- GS $4.96
- AMGN $2.18
- P/E Ratio
- GS $12.95
- AMGN $41.37
- Revenue Growth
- GS 15.34
- AMGN 18.57
- 52 Week Low
- GS $383.41
- AMGN $253.30
- 52 Week High
- GS $672.19
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- GS 25.82
- AMGN 56.84
- Support Level
- GS $523.13
- AMGN $308.64
- Resistance Level
- GS $545.00
- AMGN $335.88
- Average True Range (ATR)
- GS 21.10
- AMGN 8.04
- MACD
- GS -10.55
- AMGN -0.55
- Stochastic Oscillator
- GS 3.98
- AMGN 29.10
About GS Goldman Sachs Group Inc. (The)
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.